Oramed Pharma Shares Fall After Additional Data From Oral Insulin Study

  • Oramed Pharmaceuticals Inc ORMP has announced additional data from its Phase 2 trial (ORA-D-N02) of oral insulin candidate (ORMD-0801) to reduce liver fat content in Type 2 Diabetes patients with non-alcoholic steatohepatitis (NASH). 
  • Overall, the Phase 2 trial proved that ORMD-0801 might be a potential candidate for reducing liver fat, stiffness, and lipids in patients with T2D and NASH.
  • Related: Oramed Oral Insulin Shows Evidence For NASH Treatment.
  • The whole Liver showed a placebo-adjusted mean decrease in liver fat content of 0.96 with a placebo-adjusted median decrease of 6.0 for ORMD-0801.
  • Median Change from Baseline to Week 12 in Fibrosis Median (kPa) showed a placebo-adjusted median decrease of 1.1 for ORMD-0801. 
  • Median change from Baseline to Week 12 in Steatosis Median (dB/m) showed a placebo-adjusted median decrease of 29 for ORMD-0801.
  • The mean Change from Baseline to Week 12 in Total Cholesterol (mmol/L) showed a placebo-adjusted mean decrease of 0.40 for ORMD-0801. Results were similar for LDL, HDL, and Triglycerides.
  • Price Action: ORMP shares are down 3.40% at $7.95 on the last check Thursday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsHealth CareSmall CapMoversTrading IdeasGeneralBriefswhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!